| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CPDD.16 |
| P698 | PubMed publication ID | 27121669 |
| P50 | author | Gerhard Nehmiz | Q56462163 |
| P2093 | author name string | Hans J Woerle | |
| Leo Seman | |||
| Sreeraj Macha | |||
| Bailuo Ren | |||
| Gudrun Simons | |||
| Klaus Dugi | |||
| Sabine Pinnetti | |||
| P2860 | cites work | Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats | Q24563606 |
| Renal gluconeogenesis: its importance in human glucose homeostasis | Q32050169 | ||
| Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis | Q33880174 | ||
| The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus | Q33888236 | ||
| SGLT2 inhibition--a novel strategy for diabetes treatment | Q34117872 | ||
| Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications | Q34120717 | ||
| Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors | Q34222752 | ||
| Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes | Q34227891 | ||
| Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program | Q35568881 | ||
| Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes | Q37139427 | ||
| Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. | Q37645623 | ||
| Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going | Q37703703 | ||
| Glucagon regulation of energy metabolism | Q37728373 | ||
| Glucose handling by the kidney | Q37848041 | ||
| Effect of kidney disease on glucose handling (including genetic defects). | Q37848047 | ||
| The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. | Q37940036 | ||
| Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus | Q38005020 | ||
| Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. | Q41015653 | ||
| Learning from glycosuria | Q42641850 | ||
| Renal compensation for impaired hepatic glucose release during hypoglycemia in type 2 diabetes: further evidence for hepatorenal reciprocity | Q44452992 | ||
| Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. | Q46046433 | ||
| Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects | Q46171594 | ||
| Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes | Q46818617 | ||
| Effect of aging on glucose homeostasis: accelerated deterioration of beta-cell function in individuals with impaired glucose tolerance | Q46847394 | ||
| Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey | Q46966712 | ||
| Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. | Q51366978 | ||
| Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Q57412648 | ||
| Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects | Q83764954 | ||
| Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects | Q84856868 | ||
| Effect of non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment | Q94706800 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 152-161 | |
| P577 | publication date | 2013-03-27 | |
| P1433 | published in | Clinical pharmacology in drug development | Q27726600 |
| P1476 | title | Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects | |
| P478 | volume | 2 |
| Q89531310 | A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis |
| Q36960633 | A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes |
| Q38537119 | A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans |
| Q50454359 | Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers. |
| Q26749281 | Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes |
| Q34397646 | Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus |
| Q87809056 | Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial |
| Q45442620 | Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia |
| Q49617047 | Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization |
| Q50106084 | Empagliflozin Increases Short-Term Urinary Volume Output in Artificially Induced Syndrome of Inappropriate Antidiuresis |
| Q37278239 | Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial |
| Q38863649 | Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials |
| Q38258643 | Empagliflozin for the treatment of type 2 diabetes |
| Q44251536 | Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial |
| Q34502358 | Empagliflozin in the treatment of type 2 diabetes: evidence to date |
| Q51320301 | Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. |
| Q38364908 | Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence |
| Q38577303 | Empagliflozin/Linagliptin: A Review in Type 2 Diabetes |
| Q33837017 | Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes |
| Q38255999 | Empagliflozin: a review of its use in patients with type 2 diabetes mellitus |
| Q38175467 | Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations |
| Q39000172 | Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes |
| Q38822815 | Impact of empagliflozin in patients with diabetes and heart failure |
| Q38285582 | Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus |
| Q42234492 | Pharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS and Comparison with Other Ethnic Populations |
| Q37589626 | Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor |
| Q38389823 | Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease |
| Q47998377 | Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment |
| Q33607764 | Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus |
| Q47998345 | Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment |
| Q37239278 | Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes |
| Q38195440 | SGLT inhibitors in management of diabetes |
| Q90676214 | SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects |
| Q91599044 | SGLT2 Inhibitors for Type 2 Diabetes Mellitus Treatment |
| Q38619164 | SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment |
| Q34400029 | SGLT2 inhibitors act from the extracellular surface of the cell membrane |
| Q63071416 | SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review |
| Q37468469 | Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus |
| Q28079134 | Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review |
| Q24563917 | The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review |
| Q38908779 | The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes |
| Q35592873 | The role of empagliflozin in the management of type 2 diabetes by patient profile |
| Q36828139 | The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study |
Search more.